How much profit has Biomerieux made this year?
Biomerieux has made 544.7 M EUR this year.
Biomerieux Net Income 2025
Biomerieux Net Income
544.7 M EUR
Ticker
BIM.PA
ISIN
FR0013280286
WKN
A2DXZH
In 2025, Biomerieux's profit amounted to 544.7 M EUR, a 11.69% increase from the 487.68 M EUR profit recorded in the previous year.
The Biomerieux Net Income history
| YEAR | NET INCOME (undefined EUR) |
|---|---|
| 2028e | 809.38 |
| 2027e | 725.82 |
| 2026e | 618.47 |
| 2025e | 544.7 |
| 2024e | 487.68 |
| 2023 | 357.6 |
| 2022 | 452.4 |
| 2021 | 601.1 |
| 2020 | 404.4 |
| 2019 | 272.8 |
| 2018 | 256.5 |
| 2017 | 238.1 |
| 2016 | 179.1 |
| 2015 | 110.5 |
| 2014 | 134.9 |
| 2013 | 164.3 |
| 2012 | 134.4 |
| 2011 | 158.2 |
| 2010 | 158.7 |
| 2009 | 147.8 |
| 2008 | 129.9 |
| 2007 | 98 |
| 2006 | 105.3 |
| 2005 | 90.1 |
| 2004 | 79.7 |
Biomerieux Revenue, EBIT, Net Income FR0013280286 · A2DXZH
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Biomerieux, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Biomerieux from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Biomerieux’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Biomerieux. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Biomerieux’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Biomerieux’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Biomerieux’s growth potential.
Biomerieux Revenue, EBIT and net profit per share
| Date | Biomerieux Revenue | Biomerieux EBIT | Biomerieux Net Income |
|---|---|---|---|
| 2028e | 5.41 B undefined | 1.02 B undefined | 809.38 M undefined |
| 2027e | 5.04 B undefined | 892.37 M undefined | 725.82 M undefined |
| 2026e | 4.63 B undefined | 804.99 M undefined | 618.47 M undefined |
| 2025e | 4.29 B undefined | 710.08 M undefined | 544.7 M undefined |
| 2024e | 3.99 B undefined | 631.21 M undefined | 487.68 M undefined |
| 2023 | 3.67 B undefined | 439 M undefined | 357.6 M undefined |
| 2022 | 3.59 B undefined | 587.2 M undefined | 452.4 M undefined |
| 2021 | 3.38 B undefined | 784.3 M undefined | 601.1 M undefined |
| 2020 | 3.12 B undefined | 552.8 M undefined | 404.4 M undefined |
| 2019 | 2.67 B undefined | 370.7 M undefined | 272.8 M undefined |
| 2018 | 2.42 B undefined | 346.1 M undefined | 256.5 M undefined |
| 2017 | 2.29 B undefined | 314.9 M undefined | 238.1 M undefined |
| 2016 | 2.1 B undefined | 272.6 M undefined | 179.1 M undefined |
| 2015 | 1.96 B undefined | 228.3 M undefined | 110.5 M undefined |
| 2014 | 1.7 B undefined | 202.8 M undefined | 134.9 M undefined |
| 2013 | 1.59 B undefined | 253 M undefined | 164.3 M undefined |
| 2012 | 1.57 B undefined | 260.9 M undefined | 134.4 M undefined |
| 2011 | 1.43 B undefined | 247.2 M undefined | 158.2 M undefined |
| 2010 | 1.36 B undefined | 249.7 M undefined | 158.7 M undefined |
| 2009 | 1.22 B undefined | 226.5 M undefined | 147.8 M undefined |
| 2008 | 1.11 B undefined | 190.4 M undefined | 129.9 M undefined |
| 2007 | 1.06 B undefined | 178.1 M undefined | 98 M undefined |
| 2006 | 1.04 B undefined | 149.4 M undefined | 105.3 M undefined |
| 2005 | 993.6 M undefined | 139 M undefined | 90.1 M undefined |
| 2004 | 929.3 M undefined | 130.4 M undefined | 79.7 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 929.3 M EUR | 130.4 M EUR | 79.7 M EUR |
| 2005 | 993.6 M EUR | 139 M EUR | 90.1 M EUR |
| 2006 | 1.04 B EUR | 149.4 M EUR | 105.3 M EUR |
| 2007 | 1.06 B EUR | 178.1 M EUR | 98 M EUR |
| 2008 | 1.11 B EUR | 190.4 M EUR | 129.9 M EUR |
| 2009 | 1.22 B EUR | 226.5 M EUR | 147.8 M EUR |
| 2010 | 1.36 B EUR | 249.7 M EUR | 158.7 M EUR |
| 2011 | 1.43 B EUR | 247.2 M EUR | 158.2 M EUR |
| 2012 | 1.57 B EUR | 260.9 M EUR | 134.4 M EUR |
| 2013 | 1.59 B EUR | 253 M EUR | 164.3 M EUR |
| 2014 | 1.7 B EUR | 202.8 M EUR | 134.9 M EUR |
| 2015 | 1.96 B EUR | 228.3 M EUR | 110.5 M EUR |
| 2016 | 2.1 B EUR | 272.6 M EUR | 179.1 M EUR |
| 2017 | 2.29 B EUR | 314.9 M EUR | 238.1 M EUR |
| 2018 | 2.42 B EUR | 346.1 M EUR | 256.5 M EUR |
| 2019 | 2.67 B EUR | 370.7 M EUR | 272.8 M EUR |
| 2020 | 3.12 B EUR | 552.8 M EUR | 404.4 M EUR |
| 2021 | 3.38 B EUR | 784.3 M EUR | 601.1 M EUR |
| 2022 | 3.59 B EUR | 587.2 M EUR | 452.4 M EUR |
| 2023 | 3.67 B EUR | 439 M EUR | 357.6 M EUR |
| 2024e | 3.99 B EUR | 631.21 M EUR | 487.68 M EUR |
| 2025e | 4.29 B EUR | 710.08 M EUR | 544.7 M EUR |
| 2026e | 4.63 B EUR | 804.99 M EUR | 618.47 M EUR |
| 2027e | 5.04 B EUR | 892.37 M EUR | 725.82 M EUR |
| 2028e | 5.41 B EUR | 1.02 B EUR | 809.38 M EUR |
Biomerieux stock margins FR0013280286 · A2DXZH
The Biomerieux margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biomerieux. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biomerieux.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Biomerieux's sales revenue. A higher gross margin percentage indicates that the Biomerieux retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Biomerieux's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Biomerieux's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Biomerieux's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Biomerieux. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Biomerieux's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Biomerieux Margin History
| Biomerieux Gross margin | Biomerieux Profit margin | Biomerieux EBIT margin | Biomerieux Profit margin |
|---|---|---|---|
| 2028e | 55.99 % | 18.94 % | 14.97 % |
| 2027e | 55.99 % | 17.72 % | 14.42 % |
| 2026e | 55.99 % | 17.39 % | 13.36 % |
| 2025e | 55.99 % | 16.56 % | 12.7 % |
| 2024e | 55.99 % | 15.83 % | 12.23 % |
| 2023 | 55.99 % | 11.95 % | 9.73 % |
| 2022 | 55.97 % | 16.36 % | 12.6 % |
| 2021 | 59.26 % | 23.23 % | 17.8 % |
| 2020 | 56.24 % | 17.73 % | 12.97 % |
| 2019 | 54.83 % | 13.86 % | 10.2 % |
| 2018 | 53.79 % | 14.29 % | 10.59 % |
| 2017 | 52.96 % | 13.76 % | 10.41 % |
| 2016 | 52.33 % | 12.96 % | 8.52 % |
| 2015 | 50.35 % | 11.62 % | 5.62 % |
| 2014 | 49.45 % | 11.94 % | 7.94 % |
| 2013 | 51.93 % | 15.93 % | 10.35 % |
| 2012 | 51.87 % | 16.62 % | 8.56 % |
| 2011 | 53.33 % | 17.32 % | 11.08 % |
| 2010 | 53.21 % | 18.4 % | 11.69 % |
| 2009 | 53.92 % | 18.51 % | 12.08 % |
| 2008 | 53.4 % | 17.15 % | 11.7 % |
| 2007 | 53.24 % | 16.76 % | 9.22 % |
| 2006 | 52.26 % | 14.41 % | 10.16 % |
| 2005 | 52.38 % | 13.99 % | 9.07 % |
| 2004 | 53.48 % | 14.03 % | 8.58 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 53.48 % | 14.03 % | 8.58 % |
| 2005 | 52.38 % | 13.99 % | 9.07 % |
| 2006 | 52.26 % | 14.41 % | 10.16 % |
| 2007 | 53.24 % | 16.76 % | 9.22 % |
| 2008 | 53.4 % | 17.15 % | 11.7 % |
| 2009 | 53.92 % | 18.51 % | 12.08 % |
| 2010 | 53.21 % | 18.4 % | 11.69 % |
| 2011 | 53.33 % | 17.32 % | 11.08 % |
| 2012 | 51.87 % | 16.62 % | 8.56 % |
| 2013 | 51.93 % | 15.93 % | 10.35 % |
| 2014 | 49.45 % | 11.94 % | 7.94 % |
| 2015 | 50.35 % | 11.62 % | 5.62 % |
| 2016 | 52.33 % | 12.96 % | 8.52 % |
| 2017 | 52.96 % | 13.76 % | 10.41 % |
| 2018 | 53.79 % | 14.29 % | 10.59 % |
| 2019 | 54.83 % | 13.86 % | 10.2 % |
| 2020 | 56.24 % | 17.73 % | 12.97 % |
| 2021 | 59.26 % | 23.23 % | 17.8 % |
| 2022 | 55.97 % | 16.36 % | 12.6 % |
| 2023 | 55.99 % | 11.95 % | 9.73 % |
| 2024e | 55.99 % | 15.83 % | 12.23 % |
| 2025e | 55.99 % | 16.56 % | 12.7 % |
| 2026e | 55.99 % | 17.39 % | 13.36 % |
| 2027e | 55.99 % | 17.72 % | 14.42 % |
| 2028e | 55.99 % | 18.94 % | 14.97 % |
Biomerieux Aktienanalyse
What does Biomerieux do?
Biomerieux SA is a French company that operates in the field of in vitro diagnostics. The company was founded in 1963 by French biologist Alain Merieux and has since continued to grow. Today, Biomerieux employs around 12,000 people in over 150 countries worldwide and is listed on the Paris Stock Exchange. Biomerieux's business model is based on the development, production, and marketing of diagnostic products for various areas of medicine. This includes infectious diseases, cancer, and cardiovascular diseases. The company is divided into two main business segments: Clinical Diagnostics and Industrial Microbiology. Under the Clinical Diagnostics segment, Biomerieux offers a wide range of diagnostic products for infectious diseases, including molecular diagnostics, blood-based tests, and laboratory automation solutions. Some of the most well-known products include the VIDAS immunodiagnostic test, the FilmArray multiplex PCR test, and the VITEK automated system for microorganism identification. Under the Industrial Microbiology segment, Biomerieux is a leading provider of products for the microbiological analysis of food, beverages, and pharmaceutical products. The company offers a wide range of products for microbiological quality control, which help ensure the safety and quality of food and pharmaceutical products. These include the TEMPO system for assessing microorganism growth and the Bactalert blood culture system for rapid detection of bacteria in blood cultures. In addition to its main business segments, Biomerieux also offers specialty products for use in veterinary diagnostics and water analysis. The company works closely with clinical laboratories and health authorities to improve the diagnosis of infectious diseases and combat epidemics. Over the years, Biomerieux has built a strong research and development department focused on developing innovative diagnostic products. The company has also made a number of strategic acquisitions to expand its product portfolio and enter new markets. For example, in 2020, Biomerieux acquired Suzhou Hybiome Biomedical Engineering in China to strengthen its presence in the Chinese market. In summary, Biomerieux is a leading company in the field of in vitro diagnostics. Its wide range of products and global network make it an important partner for laboratories, hospitals, and the food and pharmaceutical industries. With its strong research and development department and strategic acquisitions, Biomerieux will continue to play a crucial role in the fight against infectious diseases and the improvement of patient care. Biomerieux ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Biomerieux's Profit Margins
The profit margins of Biomerieux represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Biomerieux's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Biomerieux's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Biomerieux's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Biomerieux’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Biomerieux stock
How has the profit developed compared to last year?
The profit has increased by 11.69% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Biomerieux publish its earnings?
Biomerieux publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Biomerieux?
The profits of Biomerieux are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Biomerieux?
You can learn more about the earnings of Biomerieux by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Biomerieux pay?
Over the past 12 months, Biomerieux paid a dividend of 0.85 EUR . This corresponds to a dividend yield of about 0.74 %. For the coming 12 months, Biomerieux is expected to pay a dividend of 0.94 EUR.
What is the dividend yield of Biomerieux?
The current dividend yield of Biomerieux is 0.74 %.
When does Biomerieux pay dividends?
Biomerieux pays a quarterly dividend. This is distributed in the months of July, July, July, July.
How secure is the dividend of Biomerieux?
Biomerieux paid dividends every year for the past 24 years.
What is the dividend of Biomerieux?
For the upcoming 12 months, dividends amounting to 0.94 EUR are expected. This corresponds to a dividend yield of 0.81 %.
In which sector is Biomerieux located?
Biomerieux is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biomerieux kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biomerieux from 6/11/2024 amounting to 0.85 EUR, you needed to have the stock in your portfolio before the ex-date on 6/7/2024.
When did Biomerieux pay the last dividend?
The last dividend was paid out on 6/11/2024.
What was the dividend of Biomerieux in the year 2024?
In the year 2024, Biomerieux distributed 0.85 EUR as dividends.
In which currency does Biomerieux pay out the dividend?
The dividends of Biomerieux are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Biomerieux stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Biomerieux
Our stock analysis for Biomerieux Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biomerieux Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
